Drug Resistance in the Treatment of Cancer

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.